enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Ionis Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And ...

   www.aol.com/news/ionis-pharmaceuticals-inc-just...

   A week ago, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) came out with a strong set of annual numbers that could... Ionis Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been ...

3. Ionis Pharmaceuticals (IONS) Q3 Earnings and Revenues Beat ...

   www.aol.com/news/ionis-pharmaceuticals-ions-q3...

   Do the numbers hold clues to what lies ahead for the stock? Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 158.06% and 11.66%, respectively, for the quarter ended ...

4. Why Ionis Pharmaceuticals (IONS) Might Surprise This ... - AOL

   www.aol.com/news/why-ionis-pharmaceuticals-ions...

   Ionis Pharmaceuticals (IONS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

5. Stock market prediction - Wikipedia

   en.wikipedia.org/wiki/Stock_market_prediction

   The successful prediction of a stock's future price could yield significant profit. The efficient market hypothesis suggests that stock prices reflect all currently available information and any price changes that are not based on newly revealed information thus are inherently unpredictable. Others disagree and those with this viewpoint possess ...

6. Ionis Pharmaceuticals - Wikipedia

   en.wikipedia.org/wiki/Ionis_Pharmaceuticals

   Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics.The company has three commercially approved medicines: Spinraza (), Tegsedi (), and Waylivra (Volanesorsen), and has four drugs in pivotal studies: tominersen for Huntington's disease (together with Roche), tofersen for SOD1-ALS, AKCEA ...

7. Ionis (IONS) Q3 Earnings & Revenues Fall Short of Estimates - AOL

   www.aol.com/news/ionis-ions-q3-earnings-revenues...

   Ionis (IONS) incurs wider-than-expected Q3 loss. The company maintains its top-and bottom-line guidance for 2021 Ionis (IONS) Q3 Earnings & Revenues Fall Short of Estimates

8. IONIS-GCCRRx - Wikipedia

   en.wikipedia.org/wiki/IONIS-GCCRRx

   IONIS-GCCR Rx, also known as ISIS-426115, is an antiglucocorticoid which is under development by Ionis Pharmaceuticals (formerly Isis Pharmaceuticals) for the treatment of diabetes mellitus type 2. [ 1 ] [ 2 ] It has also been under investigation for the treatment of Cushing's syndrome , but no development has been reported. [ 1 ]

9. Ionis (IONS) Q1 Loss Widens Year Over Year, Sales Miss - AOL

   www.aol.com/news/ionis-ions-q1-loss-widens...

   Ionis (IONS) Q1 adjusted loss per share was wider than the year-ago figure. The company maintains its guidance for 2021. Ionis (IONS) Q1 Loss Widens Year Over Year, Sales Miss